51 results
DEF 14A
BGLC
BioNexus Gene Lab Corp.
16 Sep 24
Definitive proxy
5:20pm
”). Accordingly, a majority of our Board is “independent.” There are no family relationships among any of our Directors or executive officers.
Board … number of affirmative votes being elected as Directors, even if less than a majority. As a result, abstentions and broker non-votes will have no effect
PRE 14A
BGLC
BioNexus Gene Lab Corp.
6 Sep 24
Preliminary proxy
4:02pm
Keong Yap and Muhammad Azrul bin Abdul Hamid are “independent” as defined by The Nasdaq Stock Market (“Nasdaq”). Accordingly, a majority of our Board … elected as Directors, even if less than a majority. As a result, abstentions and broker non-votes will have no effect on the vote outcome.
THE BOARD
8-K
EX-3.1
BGLC
BioNexus Gene Lab Corp.
5 Sep 24
Amendments to Articles of Incorporation or Bylaws
1:00pm
, or any proxy of such shareholder, may call the meeting to order and a chairman shall be elected by a majority of the shareholders entitled to vote … to vote, represented in person or by proxy, shall constitute a quorum at a meeting. If a quorum is not represented at a meeting, a majority
8-K
BGLC
BioNexus Gene Lab Corp.
5 Sep 24
Amendments to Articles of Incorporation or Bylaws
1:00pm
the quorum requirement for a meeting of stockholders from a majority of the outstanding shares of the Company entitled to vote, represented in person
8-K
EX-10.1
BGLC
BioNexus Gene Lab Corp.
26 Aug 24
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
12:05pm
or adjourned meeting of the Directors shall be adopted by a simple majority vote of the Directors present, comprising at least one (1) of the Founders’ Directors … to be passed by the Board of Directors shall refer to the Shareholders of the Company.
4.14 A resolution in writing signed by a majority
DEF 14C
hnr6ahfpk2ma
29 Feb 24
Information statement
5:16pm
PRE 14C
rzgiky1y92p
26 Jan 24
Preliminary information
4:05pm
8-K
EX-4.1
dm54xeg
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
8-K
EX-1.1
bukofwmwipr6afq
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
8-K
EX-3.1
lhamgj4009
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
424B4
8r6d8bgu2dl1i6
21 Jul 23
Prospectus supplement with pricing info
3:37pm
8-K
oi6rf hm71e6vy6
20 Jul 23
Material Modifications to Rights of Security Holders
11:29am